- Record: found
- Abstract: found
- Article: not found
Temozolomide in the management of dopamine agonist-resistant prolactinomas.
B C Whitelaw
1 ,
D Dworakowska ,
N W Thomas ,
S Barazi ,
P Riordan-Eva ,
A P King ,
T Hampton ,
D B Landau ,
D Lipscomb ,
C R Buchanan ,
J A Gilbert ,
S J B Aylwin
Jun 2012
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The majority of prolactinomas respond to dopamine agonist therapy, but a proportion are resistant, requiring other treatments including surgery and/or radiotherapy. Temozolomide is an oral chemotherapy agent, which has been used as a salvage therapy to treat aggressive pituitary adenomas and carcinomas, including prolactinomas, unresponsive to all conventional treatment.